1. Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives
- Author
-
Lidia Gatto, Raffaele Lodi, Enrico Franceschi, Vincenzo Di Nunno, Alicia Tosoni, Alba A. Brandes, Gatto, Lidia, Franceschi, Enrico, Di Nunno, Vincenzo, Tosoni, Alicia, Lodi, Raffaele, and Brandes, Alba Ariela
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,MICRORNA SIGNATURE ,medicine.medical_treatment ,PERIPHERAL-BLOOD ,Predictive ,Prognostic ,Circulating microRNA ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,CEREBROSPINAL-FLUID ,Internal medicine ,Biopsy ,Biomarkers, Tumor ,medicine ,PROMOTER METHYLATION ,Humans ,Neuro‐Oncology ,Microvescicle ,Liquid biopsy ,Prospective cohort study ,Circulating tumor DNA ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Genetic heterogeneity ,CENTRAL-NERVOUS-SYSTEM ,METASTATIC NICHE FORMATION ,EXTRACELLULAR VESICLES ,Liquid Biopsy ,Biomarker ,Prognosis ,medicine.disease ,Primary tumor ,CIRCULATING TUMOR-CELLS ,MALIGNANT GLIOMAS ,Radiation therapy ,MicroRNAs ,030104 developmental biology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,MESSENGER-RNA ,Glioblastoma ,business - Abstract
Glioblastoma (GBM) is the most common primary tumor of the central nervous system. Arising from neuroepithelial glial cells, GBM is characterized by invasive behavior, extensive angiogenesis, and genetic heterogeneity that contributes to poor prognosis and treatment failure. Currently, there are several molecular biomarkers available to aid in diagnosis, prognosis, and predicting treatment outcomes; however, all require the biopsy of tumor tissue. Nevertheless, a tissue sample from a single location has its own limitations, including the risk related to the procedure and the difficulty of obtaining longitudinal samples to monitor treatment response and to fully capture the intratumoral heterogeneity of GBM. To date, there are no biomarkers in blood or cerebrospinal fluid for detection, follow-up, or prognostication of GBM. Liquid biopsy offers an attractive and minimally invasive solution to support different stages of GBM management, assess the molecular biology of the tumor, identify early recurrence and longitudinal genomic evolution, predict both prognosis and potential resistance to chemotherapy or radiotherapy, and allow patient selection for targeted therapies. The aim of this review is to describe the current knowledge regarding the application of liquid biopsy in glioblastoma, highlighting both benefits and obstacles to translation into clinical care.Implications for PracticeTo translate liquid biopsy into clinical practice, further prospective studies are required with larger cohorts to increase specificity and sensitivity. With the ever-growing interest in RNA nanotechnology, microRNAs may have a therapeutic role in brain tumors.
- Published
- 2021
- Full Text
- View/download PDF